By Josh Beckerman Shares of Cingulate, which is developing drugs using its Precision Timed Release technology, fell to a 52-week low after a 1-for-20 reverse.
Cingulate Inc Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Cingulate Inc (CING) Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
By Chris Wack Cingulate said it saw positive results from a Phase 3 adult efficacy and safety study of its lead candidate, CTx-1301, for the treatment of.